Latest preclinical findings of more novel ADCs targeting CD33, CD37, FLT3, C-type lectin-like molecule 1 (CLL-1; also known as C-type lectin domain family 12, member A, CLEC12A) and leukocyte immunoglobulin-like receptor subfamily B4 (LILRB4) highlight their clinical potential for the treatment of AML [145–151]. The gene discussed is CD33; the disease is acute myeloid leukemia.